Editas Medicine Company
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Technology:
Atrificial Vectors and Immune Cells
Industry:
Atrificial Vectors and Immune Cells
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2013-01-01
Employees Number:
101-250
Funding Status:
IPO
Investors Number:
17
Total Funding:
1151532377
Estimated Revenue:
$1M to $10M
Last Funding Date:
2021-01-21
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership